NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Exactly. Whether DCVAX's 5 year overall survival turns out to be 20%, 25%, or 30%, when the historical SOC is 5%, it just doesn't change the investment thesis. Those are 300% to 500% improvements over historical survival figures with little to no side effects, unless you count survival as a side effect.

Compare that to cancer drugs that are approved for promising ~2 months to overall survival, based on surrogate endpoint, and have untold toxicity. We are entering a new era with DCVAX that should not be underestimated.

The majority of new oncology drugs that were approved by the European Medicines Agency (EMA) from 2009 to 2013 entered the market without clear evidence that they improved survival or quality of life, according to a new report published online October 4 in the BMJ.

https://www.medscape.com/viewarticle/886604